CA
MRNA icon

Claro Advisors’s Moderna MRNA Stock Holding History

Claro Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,627
Closed -$234K – 539
2024
Q4 		$234K Sell
5,627
-1,184
-17% -$56.6K 0.03% 423
2024
Q3 		$455K Buy
6,811
+1,265
+23% +$116K 0.06% 281
2024
Q2 		$659K Buy
5,546
+108
+2% +$13.7K 0.1% 202
2024
Q1 		$579K Sell
5,438
-174
-3% -$17.5K 0.1% 212
2023
Q4 		$558K Buy
5,612
+3,333
+146% +$280K 0.12% 191
2023
Q3 		$235K Buy
2,279
+315
+16% +$35.1K 0.06% 317
2023
Q2 		$239K Sell
1,964
-36
-2% -$4.8K 0.06% 309
2023
Q1 		$307K Sell
2,000
-117
-6% -$19.3K 0.09% 247
2022
Q4 		$380K Sell
2,117
-236
-10% -$38.6K 0.12% 201
2022
Q3 		$336K Hold
2,353
– – 0.13% 180
2022
Q2 		$336K Sell
2,353
-316
-12% -$45.2K 0.13% 180
2022
Q1 		$678K Hold
2,669
– – 0.24% 106
2021
Q4 		$678K Buy
2,669
+174
+7% +$50.9K 0.24% 106
2021
Q3 		$960K Buy
2,495
+338
+16% +$125K 0.4% 63
2021
Q2 		$507K Sell
2,157
-706
-25% -$126K 0.23% 125
2021
Q1 		$375K Buy
2,863
+587
+26% +$85.1K 0.19% 138
2020
Q4 		$238K Sell
2,276
-2,444
-52% -$247K 0.13% 179
2020
Q3 		$334K Buy
+4,720
New +$329K 0.21% 130

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Claro Advisors's MRNA Position: Q1 2025 in Review

Claro Advisors sold out of Moderna (MRNA) in Q1 2025, closing a stake of 5,627 shares — an estimated $234K sold.

Claro Advisors first reported a position in MRNA in Q3 2020 and held it in 18 quarters. The position peaked at $960K in Q3 2021. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Claro Advisors reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Claro Advisors sold 5,627 Moderna shares in Q1 2025, an estimated $234K.
  • Claro Advisors first reported a position in Moderna in Q3 2020 and held it in 18 quarters.
  • Claro Advisors's Moderna position peaked at $960K in Q3 2021.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Claro Advisors's 13F filing for Q1 2025, filed 12 May 2025.